Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis

被引：4
|
作者：
Stein, Eytan M. [1 ]
Latremouille-Viau, Dominick [2 ]
Joseph, George J. [3 ]
Shi, Sherry [2 ]
Guerin, Annie [2 ]
Wu, Eric Q. [4 ]
Bonifacio, Gaetano [3 ]
Cao, Xiting [3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Anal Grp Inc, Montreal, PQ, Canada
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Anal Grp Inc, Boston, MA USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124878
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3495
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA)
    Nazha, Aziz
    Sekeres, Mikkael A.
    Garcia-Manero, Guillermo
    Barnard, John
    Al Ali, Najla H.
    Roboz, Gail J.
    Steensma, David P.
    DeZern, Amy E.
    Zimmerman, Cassie
    Jabbour, Elias
    Greenberg, Molly D.
    Lee, Sangmin
    List, Alan F.
    Kantarjian, Hagop M.
    Maciejewski, Jaroslaw P.
    Komrokji, Rami S.
    BLOOD, 2014, 124 (21)
  • [42] Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents
    Roberts, Daniel A.
    Steensma, David P.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2015, 10 (03) : 318 - 328
  • [43] Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents
    Daniel A. Roberts
    David P. Steensma
    Current Hematologic Malignancy Reports, 2015, 10 : 318 - 328
  • [44] The Effects of Hypomethylating Agents on Mutational Profiles in Patients with Myelodysplastic Syndromes
    Qiu, Jihui
    Velu, Priya
    Rosenbaum, Jason
    Babushok, Daria
    Bagg, Adam
    MODERN PATHOLOGY, 2019, 32
  • [45] The Effects of Hypomethylating Agents on Mutational Profiles in Patients with Myelodysplastic Syndromes
    Qiu, Jihui
    Velu, Priya
    Rosenbaum, Jason
    Babushok, Daria
    Bagg, Adam
    LABORATORY INVESTIGATION, 2019, 99
  • [46] Malignant pleural mesothelioma characteristics and outcomes: A SEER-Medicare analysis
    Taioli, Emanuela
    Wolf, Andrea
    Alpert, Naomi
    Rosenthal, Daniel
    Flores, Raja
    JOURNAL OF SURGICAL ONCOLOGY, 2023, 128 (01) : 134 - 141
  • [47] REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: SEER-MEDICARE ANALYSIS
    Hamlin, P.
    Satram-Hoang, S.
    Reyes, C.
    Hoang, K.
    Guduru, S.
    Skettino, S.
    HAEMATOLOGICA, 2013, 98 : 353 - 353
  • [48] Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents
    Jabbour, Elias
    Strati, Paolo
    Cabrero, Monica
    O'Brien, Susan
    Ravandi, Farhad
    Bueso-Ramos, Carlos
    Wei, Qiao
    Hu, Jianhua
    Abi Aad, Simon
    Short, Nicholas J.
    Dinardo, Courtney
    Daver, Naval
    Kadia, Tapan
    Wierda, William
    Wei, Yue
    Colla, Simona
    Borthakur, Gautam
    Cortes, Jorge
    Estrov, Zeev
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (04) : 351 - 358
  • [49] Changing treatment patterns for hepatocellular carcinoma: A SEER-Medicare study.
    Iheanacho, Franklin
    Tramontano, Angela
    Abrams, Thomas Adam
    Manz, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: An Analysis of SEER-Medicare Database
    Parikh, Neehar D.
    Marshall, Vincent D.
    Nathan, Hari
    Balkrishnan, Rajesh
    Shahinian, Vahakn
    HEPATOLOGY, 2015, 62 : 409A - 410A
12345